การเกิดเลือดออกจำนวนมากใต้ชั้นคอรอยด์หลังการฉีดยา bevacizumab เข้าน้ำวุ้นตา ในคนไข้โรคหลอดเลือดโป่งพองใต้จอประสาทตา: รายงานผู้ป่วย
คำสำคัญ:
bevacizumab, เลือดออก, ภาวะแทรกซ้อนบทคัดย่อ
References
Dimitros B, Chryssanthi K, Marilita M , Spiros P , Ioaanis L , Michael A : Massive choroidal hemorrhage after intravitreal administration of bevacizumab for AMD follow by contralateral sympathetic ophthalmia. Clinical ophthalmology 2009; 3: 457-459
Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990; 10: 1–8.
Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with vertiporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology. 2004; 111: 1576–84
CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908.
Chan W-M, Lai TYY, Tano Y, et al. Photodynamic therapy in macular diseases of Asian populations: when East meets West. Jpn J Ophthalmol 2006; 50: 161-169.
Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2010; 94: 297–301.
Lai TYY, Chan W-M, Liu DTL, et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92: 661–666.
Hikichi T, Higuchi M, Matsushita T, et al. Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol 2013; 97: 617–621.
Marcus DM, Singh H, Lott MN, et al. Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients. Retina 2013; 33: 35–47.
Chhablani JK, Narula R, Narayanan R. Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy. Indian J Ophthalmol 2013;61: 136–138.
Wakabayashi T, Gomi F, Sawa M, et al. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. Br J Ophthalmol 2012; 96: 394–399.
Hosokawa M, Shiraga F, Yamashita A, et al. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy. Br J Ophthalmol 2015; 99: 1087-1091.
Hara C, Sawa M, Sayanagi K, et al. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Retina 2016; 36: 37–45.
Lanzetta P, Loewenstein A, The Vision Academy Steering Committee (2017) Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol 255: 1259–1273.
Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF: Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013; 97: 454–459.
Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, et al Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization Am J Ophthalmol. 2006;141:456–62
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging. 2005;36:331–5
Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, et al Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Retina. 2006; 26: 495–511
Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration Am J Ophthalmol. 2006; 142: 1–9
Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, et al Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina. 2006; 26: 383–90
Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008; 92: 70–3.
Saif MW, Mehra R. Incidence and management of bevacizumab- related toxicities in colorectal cancer. Expert Opin Drug Saf. 2006; 5: 553–566.
Krishnan R, Goverdhan S, Lochhead J (2009) Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. Clin Experiment Ophthalmology 37: 384-388
Bessho H, Honda S, Imai H, Negi A (2011) Natural course and funduscopic findings of polypoidal c vasculopathy in a Japanese population over 1 year of follow-up. Retina 31: 1598-1602.
Downloads
เผยแพร่แล้ว
ฉบับ
บท
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
การละเมิดลิขสิทธิ์ถือเป็นความรับผิดชอบของผู้ส่งบทความโดยตรง
ผลงานที่ได้รับการตีพิมพ์ถือเป็นลิขสิทธิ์ของผู้นิพนธ์ ขอสงวนสิทธิ์มิให้นำเนื้อหา ทัศนะ หรือข้อคิดเห็นใด ๆ ของบทความในวารสารไปเผยแพร่ทางการค้าก่อนได้รับอนุญาตจากกองบรรณาธิการ อย่างเป็นลายลักษณ์อักษร
